I-many's Contract Management Solutions Proven Highly-Valued for Life Sciences Companies

I-many, Inc. (NASDAQ:IMNY), a leading provider of contract management software and services for the enterprise, announced the release of a research brief from Aberdeen Group, a Harte-Hanks company (NYSE: HHS), comparing the performance of companies using I-many’s contract management solutions to those Aberdeen classifies as best-in-class for life sciences companies (i.e., pharmaceuticals, biotechnology, biomedical technologies and devices). The Aberdeen Group research briefs provide a synopsis of the principal finding derived from Aberdeen’s primary research, including key performance indicators, best-in-class insight and vendor insight. Aberdeen found that enterprises utilizing I-many’s contract management solution have developed superior capabilities for managing various aspects of compliance and the contract lifecycle process. The research brief discusses findings from a December 2007 report by Aberdeen, ”Sell-Side Contract Management: Opportunity-to-Order Optimization,” that reveals I-many customers have achieved compliance performance reaching "best-in-class” levels and outpaced ‘Industry Average’ and ‘Laggard’ companies by 35% to 103%. "The Aberdeen Group’s independent research confirms how our dedication to the life sciences sector has resulted in products that enable our customers to maximize their revenue and ensure accountability,” said John Rade, president and CEO of I-many. "We are proud that our hard work and commitment have led to Aberdeen recognizing I-many’s leadership in contract management for the life sciences.” As the industry’s most comprehensive solution, the I-many Contract Management Suite for Life Sciences manages hundreds of billions of dollars in corporate contracts, revenue and pricing agreements for life sciences companies. This solution directly addresses the challenges faced by life sciences companies as they navigate the complex regulatory environment. "Life sciences companies have to work with complex contracts and expanding regulatory requirements,” said Michael Zuckerman, senior vice president of marketing at I-many. "Because of the intricacies surrounding corporate contracts and compliance, it is critical for life sciences companies to have highly effective contracting practices in place in order to make key processes more accurate. This report shows that I-many is capable of providing first-class solutions to its customers that ensure their businesses are running as efficiently and compliant as possible.” About I-many® I-many (NASDAQ:IMNY) is the leading provider of contract management software and services for the enterprise. With hundreds of customers across 21 industries worldwide, I-many is enabling businesses to manage the entire contract life cycle, from pre-contract processes and contract management to active compliance and contract optimization. The result is an end-to-end solution that provides greater levels of insight into contract performance, allowing companies to improve profitability and achieve a measurable return on investment. For more information, please visit www.imany.com. This news release contains forward-looking statements, and actual results may vary from those expressed or implied herein. Factors that could affect these results include the risk of unforeseen technical or practical impediments to planned software development and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission.